SCHEMBL25758856

SCHEMBL25758856

Cn1ncc2c(N)nnnc21

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PI4KA P42356 2/20 0.56
PI4K2B Q8TCG2 2/20 0.56
PI4K2A Q9BTU6 2/20 0.56
PI4KB Q9UBF8 2/20 0.56
ALDH1A1 P00352 2/20 0.41
PDE2A O00408 1/20 0.35
KDM4E B2RXH2 2/20 0.34
ALOX15 P16050 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
MEN1 O00255 3/20 0.33
KMT2A Q03164 3/20 0.33
XDH P47989 2/20 0.33
PKM P14618 2/20 0.33
NSD2 O96028 1/20 0.33
MAPK1 P28482 1/20 0.31
HAVCR2 Q8TDQ0 1/20 0.31
EGFR P00533 1/20 0.31
CYP1A2 P05177 1/20 0.31
TSHR P16473 1/20 0.31
CYP2C19 P33261 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22704493 0.76 CYP1A2 (0.36) PI4KAPI4K2BPI4K2API4KBALDH1A1
SCHEMBL130702 0.72 PI4KA (0.56) PI4KAPI4K2BPI4K2API4KBALDH1A1
SCHEMBL130407 0.72 PI4KA (1.00) PI4KAPI4K2BPI4K2API4KBALDH1A1
SCHEMBL4409891 0.71 PI4KA (0.55) PI4KAPI4K2BPI4K2API4KBALDH1A1
SCHEMBL130521 0.69 PDE2A (0.60) PI4KAPI4K2BPI4K2API4KBALDH1A1
SCHEMBL130798 0.69 PI4KA (0.53) PI4KAPI4K2BPI4K2API4KBALDH1A1
SCHEMBL29685062 0.69 PDE2A (0.60) PI4KAPI4K2BPI4K2API4KBALDH1A1
SCHEMBL21282826 0.67 PI4KA (0.50) PI4KAPI4K2BPI4K2API4KBALDH1A1
SCHEMBL26973527 0.67 PI4KA (0.50) PI4KAPI4K2BPI4K2API4KBALDH1A1
SCHEMBL29385938 0.67 PI4KA (0.50) PI4KAPI4K2BPI4K2API4KBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023177808-A1 MODIFIED GAPMER OLIGOMERS AND METHODS OF USE THEREOF ALIGOS THERAPEUTICS, INC. (US) 2023-09-21 WO disclosed
WO-2023122316-A2 SPLICE SWITCH OLIGONUCLEOTIDE (SSO) MOLECULES FOR TARGETING β-CATENIN AND USES THEREOF ALIGOS THERAPEUTICS, INC. (US) 2023-06-29 WO disclosed